Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China Authors: Yuxuan Zhou, Rong Tang, Mingwei Wei, Xinglu Peng, Ruifan Shen, Jingxin Li Published: 2026 ABSTRACT ABSTRACTThis study evaluates the post-marketing safety profile of a Haemophilus influenzae Type b (Hib) conjugate vaccine in children aged 3 months to 5 y in China. A prospective, observational, multi-center, post-marketing safety surveillance study of a monovalent Hib conjugate vaccine manufactured by Chengdu Olymvax Biotechnology Inc. was conducted across 20 districts in Jiangsu Province, China, from June 2020 to December 2021. The study enrolled 2,714 children in the active surveillance group and 6,347 children in the passive surveillance group. For active surveillance, guardians recorded all adverse events occurring within 30 d after each vaccine dose in diary cards, regardless of suspected causality. Serious adverse events were captured through spontaneous guardian reports or through regular investigator follow-up from the first dose through 6 months after completion of the primary Hib conjugate vaccine series. During passive surveillance, suspected adverse events following immunization (AEFI) of the Olymvax Hib vaccine were registered and reported through China National Adverse Event Following Immunization (AEFI) Surveillance System. Active surveillance revealed an overall adverse event incidence of 6.7% (181/2,714), with 6.3% (170/2,714) classified as adverse reactions, predominantly mild to moderate in severity (Grade 1–2: 6.0%; Grade 3: 0.3%). Passive surveillance identified a substantially lower adverse reaction incidence of 0.33% (21/6,347), with pyrexia (0.25%) being the most frequent. The AEFI incidence rate in passive surveillance was significantly lower than in active surveillance (P < .001). No vaccine-related serious adverse reactions were reported in either surveillance system. This post-marketing surveillance study confirms that the Hib conjugate vaccine demonstrates a favorable safety profile in children aged 3 months to 5 y, with no safety-associated risks identified.KEYWORDS: Safety, Haemophilus influenzae Type b conjugate vaccine, post-marketing surveillance study Introduction Haemophilus influenzae Type b (Hib) was historically one of the leading pathogens responsible for invasive diseases, including bacterial meningitis and severe pneumonia, in infants and young children worldwide. Its high rates of disability and mortality posed a substantial threat to public health.1 Globally, Hib accounts for more than 90% of systemic infections caused by Haemophilus influenzae, resulting in approximately 3 million severe cases annually.1 In China alone, an estimated 78,000 children under five years of age suffered from severe Hib disease in 2015, with nearly 3,400 deaths attributed to Hib infection.2 Among the various strategies for addressing Hib infections, vaccination remains the most effective and cost-efficient health intervention for preventing Hib disease. The vaccine is available as a monovalent formulation or in combination with other vaccines, with a three-dose vaccination schedule typically recommended.3 Hib vaccination programs have significantly reduced the incidence of Hib-related diseases, successfully achieving herd immunity and yielding substantial public health benefits. Post-marketing safety surveillance is a critical component of vaccine evaluation after licensure. It can be conducted through active monitoring and passive reporting systems, with the aim of identifying and evaluating adverse events following immunization, particularly common adverse reactions and potential serious safety signals. In China, post-marketing vaccine safety surveillance relies predominantly on the China National Adverse Event Following Immunization (AEFI) Surveillance System, which is a routine passive reporting mechanism. Although this system has contributed substantially to vaccine safety monitoring, passive surveillance is inherently limited by underreporting and variation in reporting completeness. For Hib vaccines, previous post-marketing safety evaluations in China have mainly been based on passive surveillance data, whereas evidence from active surveillance remains limited, especially for domestically manufactured monovalent Hib conjugate vaccines. In addition, few studies have directly compared the safety information captured by active and passive surveillance approaches in the same real-world setting. Following implementation of the Vaccine Administration Law in China in 2019, provincial-level evidence has become increasingly important for informing immunization policy decisions, including potential incorporation of Hib vaccination into public immunization programs. Therefore, this study aimed to evaluate the post-marketing safety profile of the Olymvax monovalent Hib conjugate vaccine among children aged 3 months to 5 y in Jiangsu Province using both active and passive surveillance approaches, and to compare the safety information generated by these two surveillance methods. Methods Study design and participants This prospective, observational, multi-center, post-marketing safety surveillance study of a monovalent Haemophilus influenzae Type b conjugate vaccine comprised two components: active safety surveillance and passive safety surveillance. The study was conducted across 20 districts and counties in Jiangsu Province from June 10, 2020, to December 19, 2021. Active surveillance was implemented in seven districts and counties within Jiangsu Province: Ganyu District, Lianyungang City; Haizhou District, Lianyungang City; Guannan County, Lianyungang City; Huaiyin District, Huai’an City; Jiawang District, Xuzhou City; Tongshan District, Xuzhou City; and Feng County, Xuzhou City. Passive surveillance was implemented across all twenty participating districts and counties within Jiangsu Province. The study protocol received approval from the Independent Ethics Committee of the Jiangsu Provincial Center for Disease Control and Prevention (JSJK2019-A024-03). Eligible participants were healthy children aged 3 months to 5 y. Inclusion criteria required that participants’ parents or legal guardians be able to comprehend the informed consent content and provide written informed consent. Exclusion criteria included contraindications to vaccination as listed in the vaccine package insert: individuals with acute diseases, severe chronic diseases, acute exacerbations of chronic diseases, or fever; individuals with known allergies to any vaccine component, particularly tetanus toxoid; and individuals with severe cardiovascular disease, hypertension, hepatic disease, or renal disease. Study vaccination The monovalent Haemophilus influenzae Type b conjugate vaccine used in this study was manufactured by Chengdu Olymvax Biotechnology Inc., Chengdu, China. The vaccine consists of purified Hib capsular polysaccharide covalently conjugated to tetanus toxoid. Each 0.5 ml dose contains at least 10 μg of purified Hib polysaccharide as the active ingredient, with sodium chloride as the excipient. This vaccine is designed to prevent serious infections caused by Haemophilus influenzae Type b, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis. The vaccination schedule varied by age group. Infants aged 3 to 5 months received a three-dose primary series (0.5 ml per dose) administered at 0, 1, and 2 months, with a minimum interval of 28 d between doses. Infants aged 6 to 11 months received a two-dose series (0.5 ml per dose) at 0 and 1 month, also with a minimum 28-d interval. Children aged 1 to 5 y received a single 0.5 ml dose. Safety surveillance Active safety surveillance Active surveillance data were primary data prospectively collected by study investigators and participating guardians in the seven selected districts/counties. After each vaccination, guardians were instructed to record all adverse events occurring within 30 d using standardized diary cards, regardless of whether they considered the events related to vaccination. These data were not extracted from vaccination cards. Instead, investigators conducted scheduled follow-up to collect, review, and verify the reported information and to obtain additional clinical details when necessary. Investigators assessed the relationship between each reported event and vaccination according to the study procedures, considering the temporal relationship, clinical characteristics, alternative explanations, medical history, concomitant medications, co-administered vaccines where relevant, and biological plausibility. Events assessed as related to vaccination were classified as adverse reactions. When medical evaluation was required, information was verified using clinical records and assessment from healthcare professionals, including immunization or treating physicians where applicable. Serious adverse events were captured through spontaneous guardian reports or through regular investigator follow-up from the first dose through 6 months after completion of the primary vaccination series. Throughout the surveillance period, all concomitant medications (excluding vitamins and dietary supplements) and concomitant vaccinations administered between vaccination and safety data collection were documented. When a serious adverse event occurred, complete case documentation was required, including treatment details. Adverse reaction severity was graded according to the Technical Guidelines for Clinical Comparability Studies of Preventive Vaccines (No. 102 of 2019) issued by the China National Medical Products Administration. Passive safety surveillance Passive surveillance data were secondary data extracted from the routine China National Adverse Event Following Immunization (AEFI) Surveillance System for eligible recipients of the Olymvax Hib vaccine in the 20 participating districts/counties during the study period. In routine practice, suspected AEFI are generally identified during post-vaccination observation, medical visits, or guardian-initiated consultation with healthcare personnel, and are then reported by vaccination providers, healthcare institutions, or public health staff. Guardians do not directly submit reports to a public web portal; instead, adverse event information is entered into the national surveillance system by authorized healthcare or public health personnel according to established procedures. Only records linked to the Olymvax monovalent Hib vaccine were extracted and analyzed in this study. Although other Hib-containing vaccine products may have been available in some participating areas during the study period, records related to those products were not included in the present analysis. Statistical analysis For the active surveillance component, the sample size was determined according to the practical objective of post-marketing vaccine safety monitoring, namely to provide sufficient sensitivity for detecting common and relatively uncommon adverse reactions under real-world conditions. In vaccine safety surveillance, a sample size approaching 3,000 participants is generally considered capable of providing a high probability of detecting at least one event with a true incidence of approximately 0.1%. The final active surveillance cohort included 2,714 children, which was considered adequate for characterizing the short-term safety profile of the vaccine while remaining feasible for implementation across participating sites. For the passive surveillance component, no formal prospective sample size calculation was performed. Instead, all eligible recipients of the Olymvax Hib vaccine captured through the routine surveillance system in the 20 participating districts/counties during the study period were included. The safety set (SS) comprised data from both active and passive surveillance components. Participants who received at least one vaccine dose and had at least one safety evaluation were included in the SS. Baseline characteristics and adverse events/reactions were summarized using descriptive statistics. Quantitative variables were expressed as mean (standard deviation), whereas qualitative variables were presented as rates or proportions. The incidence of adverse events/reactions was calculated as the ratio of doses associated with adverse events/reactions to the total number of doses administered. All statistical analyses were performed using SAS Software version 9.4. Results Demographic data and baseline medical characteristics A total of 2,714 participants were enrolled in the active surveillance group, comprising 751 children aged 3–5 months, 803 aged 6–11 months, and 1,160 aged 1–5 y. All 2,714 participants who completed the first dose of vaccination were included in the SS. The mean age was 0.37 (0.07) years in the 3–5 month age group, with 383 (51.0%) males and 368 (49.0%) females; 0.74 (0.13) years in the 6–11 month age group, with 445 (55.4%) males and 358 (44.6%) females; and 2.14 (1.15) years in the 1–5 y age group, with 599 (51.6%) males and 561 (48.4%) females. Vaccination series completion rates varied by age group: 600 subjects (79.9%) in the 3–5 month age group completed the three-dose series, 711 subjects (88.5%) in the 6–11 month age group completed the two-dose series, and all subjects in the 1–5 year age group received the single required dose. Overall compliance was satisfactory, with detailed data presented in Table 1. The primary reason for incomplete immunization was voluntary withdrawal from the study. Table 1.Demographic characteristics and subject compliance. 3–5 month age groupn (%)6–11 month age groupn (%)1–5 year age groupn (%)Totaln (%)Active surveillance Age, years0.37(0.07)0.74(0.13)2.46(1.15)1.37(1.22)Sex Male383 (51.0)445 (55.4)599 (51.6)1,427 (52.6)Female368 (49.0)358 (44.6)561 (48.4)1,287 (47.4)Completed first dose Yes751 (100)803 (100)1160 (100)2714 (100)Completed second dose Yes664 (88.4)711 (88.5)–1375 (88.5)No87 (11.6)92 (11.5)–179 (11.5)Completed third dose Yes602 (80.2)––602 (80.2)No149 (19.8)––149 (19.8)Passive surveillance Completed first dose Yes1,332 (100)1,504 (100)3,511 (100)6,347 (100)Completed second dose Yes1,090 (81.8)1,050 (69.8)–2,140 (75.5)No242 (18.2)454 (30.2)–696 (24.5)Completed third dose Yes625 (46.9)––625 (46.9)No707 (53.1)––707 (53.1)SD: standard deviation; N: number of individuals per dataset. Age = (Date of informed consent - Date of birth) / 365.25. Data are presented as n (%), unless otherwise specified. Second dose vaccination statistics apply only to the 3-5 month-old and 6-11 month-old cohorts. Third dose vaccination statistics apply only to the 3-5 month-old cohort. Demographic characteristics and subject compliance. SD: standard deviation; N: number of individuals per dataset. Age = (Date of informed consent - Date of birth) / 365.25. Data are presented as n (%), unless otherwise specified. Second dose vaccination statistics apply only to the 3-5 month-old and 6-11 month-old cohorts. Third dose vaccination statistics apply only to the 3-5 month-old cohort. In the passive surveillance group, 6,347 subjects were enrolled, including 1,332 children aged 3–5 months, 1,504 aged 6–11 months, and 3,511 aged 1–5 y. Vaccination series completion rates were as follows: 625 subjects (46.9%) in the 3–5 month age group completed the three-dose series, 1,050 subjects (69.8%) in the 6–11 month age group completed the two-dose series, and all subjects in the 1–5 y age group received the single required dose. Compliance was satisfactory in the 6–11 month and 1–5 y age groups, whereas the 3–5 month age group demonstrated lower compliance (Table 1). Incidence and characteristics of adverse reactions Active surveillance identified an overall adverse event incidence of 6.7% (181/2,714). Among these, 170 cases (6.3%) were determined to be vaccine-related adverse reactions, predominantly mild to moderate in severity (Grade 1–2: 6.0%; Grade 3: 0.3%). No serious adverse reactions occurred across any age group. In contrast, passive surveillance through the Chinese AEFI Monitoring Information System detected 21 cases (0.33%) of adverse reactions related to the Olymvax Hib vaccine. Similarly, no serious adverse reactions were reported in any age group under passive surveillance. Active monitoring identified seven types of injection site adverse reactions: erythema (2.43%), induration (1.51%), swelling (1.25%), pain (0.63%), rash (0.26%), pruritus (0.26%), and cellulitis (0.07%). Nine types of systemic adverse reactions were observed, with pyrexia being most prevalent (2.91%), followed by diarrhea (0.44%), decreased appetite (0.29%), and vomiting (0.11%). The remaining systemic adverse reactions occurred in only 1–2 cases each, with incidence rates below 0.10%. Passive surveillance identified three types of local injection site reactions: erythema (0.05%), induration (0.02%), and swelling (0.05%). Ten types of systemic adverse reactions were documented, with pyrexia (0.25%) and vomiting (0.05%) being most common. All other systemic adverse reactions occurred in only 1–2 cases, with incidence rates below 0.05%. Pyrexia emerged as the most common systemic adverse reaction across both surveillance methods. Notably, injection site adverse reactions were detected more frequently through active surveillance. The overall incidence of adverse reactions was significantly lower in passive surveillance compared to active surveillance (P < .001) (Table 2). Table 2.Distribution of adverse reaction clinical manifestations and reporting incidence in active and passive surveillance.Type of adverse reactionsActive surveillance(n = 2,714)Passive surveillance(n = 6,347)χ2PInjection-site adverse reactions Erythema66 (2.43)3 (0.05) Induration41 (1.51)1 (0.02) Swelling34 (1.25)3 (0.05) Pain17 (0.63)– Rash7 (0.26)– Pruritus7 (0.26)– Cellulitis2 (0.07)– Systemic adverse reactions Pyrexia79 (2.91)16 (0.25) Diarrhea12 (0.44)2 (0.03) Decreased appetite8 (0.29)1 (0.02) Vomiting3 (0.11)3 (0.05) Total170 (6.3)21 (0.3)350.3950.000**Data are presented as n (%), unless otherwise specified. The P-value was calculated based on intergroup comparisons using the chi-square test or Fisher’s exact test. **P < .001. Distribution of adverse reaction clinical manifestations and reporting incidence in active and passive surveillance. Data are presented as n (%), unless otherwise specified. The P-value was calculated based on intergroup comparisons using the chi-square test or Fisher’s exact test. **P < .001. Concomitant medication and vaccination in active surveillance For participants in the active safety observation group, investigators assessed concomitant medication use and vaccination history during the interval between vaccine administration and adverse reaction/event collection. Among the 3–5 month age cohort, 5 subjects (0.6%) received concomitant medications, while 247 subjects (32.9%) received concurrent vaccine administration. In the 6–11 month age cohort, 15 subjects (1.9%) received concomitant medications, and 129 subjects (16.1%) received concurrent vaccines. Among the 1–5 y age cohort, 8 subjects (0.7%) received concomitant medications, and 51 subjects (4.4%) received concurrent vaccines (Table 3). Combination medication primarily comprises the following seven categories, namely: unspecified herbal and traditional medicines, propionic acid derivatives, phenoxyethylamine derivatives, broad-spectrum penicillins, other intestinal, anti-inflammatory/anti-infective agents, third-generation cephalosporins and corticosteroids. Table 3.Concomitant medication and vaccination. 3–5 month age group(N = 751)6–11 month age group(N = 803)1–5 year age group(N = 1,160)Total(N = 2,714)Concomitant medication Yes5 (0.7)15 (1.9)8 (0.7)28 (1.0)No746 (99.3)788 (98.1)1152 (99.3)2686 (99.0)Concomitant vaccination Yes247 (32.9)129 (16.1)51 (4.4)427 (15.7)No504 (67.1)674 (83.9)1,109 (95.6)2,287 (84.3)Data are presented as n (%), unless otherwise specified. Concomitant medication and vaccination. Data are presented as n (%), unless otherwise specified. Discussion Although passive surveillance remains a widely adopted method for monitoring AEFI globally, it has inherent limitations. Research has demonstrated that establishing an active post-marketing vaccine safety surveillance system can effectively address these shortcomings. Active surveillance enhances the sensitivity of AEFI detection while simultaneously providing a mechanism to validate safety signals identified through passive surveillance systems.4,5 Consequently, this study compared adverse reactions captured through both active and passive surveillance methodologies to evaluate the effectiveness of different monitoring approaches for assessing Hib conjugate vaccine safety. The results of this post-marketing safety surveillance study demonstrate a favorable safety profile for the Hib conjugate vaccine in Chinese children aged 3 months to 5 y. Across both surveillance methods, no serious adverse events or vaccine-related severe adverse reactions were reported, findings that align with the established safety characteristics of Hib vaccines documented in global safety databases.6–8 Active surveillance revealed an overall adverse event incidence of 6.7% (181/2,714), with 6.3% (170/2,714) classified as adverse reactions. These reactions were predominantly mild to moderate in severity (Grade 1–2: 6.0%; Grade 3: 0.3%), consistent with findings from previous studies. For instance, a multicenter, non-controlled active surveillance study conducted in China among children aged 3 to 60 months yielded a comparable overall reporting rate of 5.6%.9 The most common injection-site adverse reactions were erythema (2.43%), induration (1.51%), and swelling (1.25%). Systemic adverse reactions were primarily pyrexia (2.91%) and diarrhea (0.44%), which aligned with results from previous Chinese studies.10 Notably, among the 170 adverse reactions documented, 129 (75.9%) occurred following the first vaccine dose. The incidence of adverse reactions demonstrated a dose-dependent pattern, with both general and abnormal reactions occurring more frequently after the first dose compared to subsequent doses, a finding consistent with domestic research reports.11 Passive surveillance data from 6,347 subjects further reinforced the vaccine’s favorable safety profile, with a low adverse reaction incidence of 0.33% (21 cases); pyrexia (0.25%) was the most frequently reported reaction. Compared with existing passive safety monitoring data from Jiangsu Province during the same period (0.07%), our study demonstrated a higher incidence of adverse reactions, which may be attributed to differences in sample size and reporting completeness between the two surveillance approaches.12 The incidence of adverse events in passive surveillance (0.3%) was significantly lower than in active surveillance (6.3%), with this difference reaching statistical significance (P < .001). This discrepancy can be attributed to the inherent strengths of active surveillance, which employs rigorously designed protocols, standardized data collection procedures, and systematic personnel training to enable more comprehensive and accurate capture of adverse event data. Consequently, active surveillance provides distinct advantages in characterizing both the incidence and determinants of adverse events.13 Conversely, passive surveillance depends on spontaneous reporting by healthcare professionals and patients, making it susceptible to multiple confounding factors including reporter awareness of adverse reactions, procedural complexity, and reporting motivation. These factors collectively contribute to substantial underreporting and underestimation of true adverse event rates, thereby highlighting the inherent limitations of passive surveillance systems.13,14 An important finding of this study is the substantial difference in adverse reaction reporting between the active and passive surveillance systems. The incidence of adverse reactions identified through passive surveillance was markedly lower than that identified through active surveillance, although neither approach detected a serious vaccine-related safety signal. This discrepancy is consistent with current understanding of post-marketing vaccine pharmacovigilance. Passive surveillance systems are indispensable for large-scale, routine signal detection, but they are influenced by reporting awareness, reporting completeness, and the tendency for mild, self-limited events to go unreported. By contrast, active surveillance is more sensitive for capturing common and transient post-vaccination reactions because it uses predefined follow-up procedures, systematic symptom collection, and structured verification of reported events. Recent guidance and methodological reviews have emphasized that active and passive surveillance should be regarded as complementary approaches in vaccine safety evaluation, particularly in the post-licensure setting.7,8 This study has several strengths. First, it evaluated the safety of a single licensed Hib vaccine product in a real-world setting, which enhances the practical relevance of the findings for routine immunization programs. Second, the study incorporated both active and passive surveillance within the same post-marketing framework, allowing direct observation of the different types and frequencies of safety information captured by these two approaches. The safety findings of this study are also broadly consistent with published data on Hib conjugate vaccines formulated with different carrier proteins. The vaccine evaluated here uses tetanus toxoid as the carrier protein. Previous studies have shown that Hib conjugate vaccines using tetanus toxoid, CRM197, or outer membrane protein complex as carrier proteins are generally well tolerated and are mainly associated with mild to moderate local reactions and transient systemic events such as fever.15,16 Several limitations warrant consideration in interpreting our findings. First, the absence of a control group precluded direct comparison between vaccinated and unvaccinated populations, potentially allowing confounding factors to influence safety assessments. Second, restricting surveillance to Jiangsu Province may have limited our ability to detect region-specific or time-specific variations in adverse reaction patterns across diverse populations. Additionally, the relatively brief surveillance period of approximately 6 months was insufficient to fully characterize the long-term post-marketing safety profile of the vaccine. Despite these constraints, this study provides valuable real-world evidence supporting the safety of Hib conjugate vaccines in routine clinical practice. Taken together, the findings indicate that the Olymvax monovalent Hib conjugate vaccine has a favorable safety profile in children aged 3 months to 5 y under routine use conditions. The study also highlights the added value of active surveillance for capturing mild and transient adverse reactions that may be substantially under-ascertained in routine passive reporting systems. Future post-marketing studies could build on these findings by using prospective comparative designs, larger populations, or linked electronic health data platforms to further strengthen real-world vaccine safety evaluation.8,17 Conclusion This post-marketing safety surveillance study evaluated the Hib conjugate vaccine through integrated active and passive adverse reaction monitoring systems. The findings demonstrate a favorable safety profile, with adverse reactions predominantly limited to those documented in the product labeling and classified as non-serious events. Active surveillance data exhibited superior completeness and sensitivity compared to passive surveillance methods, highlighting the value of comprehensive monitoring approaches in vaccine safety assessment. Biography Jingxin Li, Combining Microbiology, Epidemiology and Biostatistics, I have rich experiences in vaccine clinal trial design, including sample size calculation and implementing vaccine clinical trials as the principal investigator. I am also able to do the data analysis and to drive data-driven global health solutions associated with vaccination. I am also a full professor of epidemiology or clinical epidemiology of vaccines in Public Health, responsible for teaching and mentoring Master and PhD. students in Southeast University, Nanjing Medical University, and China Pharmaceutical University. I am a team player and a life-time learner. I have a strong interest in the clinical research of novel vaccines and the scientific research and practice of optimizing vaccine immunization strategies. Funding Statement Supported by Science Fund for Distinguished Young Scholars of Jiangsu Province [grant number: BK20220064] and Joint Program on Health Science & Technology Innovation of Hainan Province [grant number: WSJK2024MS131]. Disclosure statement No potential conflict of interest was reported by the author(s). Ethical statement The Scientific Review Committee of Jiangsu Provincial Center for Disease Control and Prevention approved the study protocol (approval number: JSJK2019-A024-03). References